Literature DB >> 2690907

Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury.

K Przyklenk1, R A Kloner.   

Abstract

1. Coronary artery reperfusion has become the treatment of choice for evolving myocardial infarction. 2. While there is no question that timely restoration of coronary blood flow is essential for the salvage of ischaemic myocardium, coronary reperfusion has also been associated with potentially deleterious consequences. Specifically, the viable tissue salvaged by reperfusion remains 'stunned'--i.e., exhibits prolonged abnormalities in contractile function--for hours to days following reflow. Furthermore, it has been suggested that reperfusion per se may lethally injure some myocytes that were only reversibly injured prior to restoration of blood flow. 3. ACE inhibitors such as captopril and enalapril have been shown to reduce indices of myocardial injury (infarct size, creatine kinase release) and enhance contractile function of stunned myocardium in experimental models of coronary occlusion followed by reperfusion. These effects of ACE inhibitors have largely been attributed to the reduction in myocardial O2-demand and increase in myocardial blood flow associated with blunting of angiotensin II formation. 4. Recent studies suggest that the effects of some ACE inhibitors--particularly captopril--may not solely be explained on the basis of ACE inhibition. In fact, sulphydryl (-SH) containing ACE inhibitors such as captopril appear to act as scavengers of oxygen-derived free radical species thought to be important in the pathogenesis of both postischaemic contractile dysfunction and ischaemia/reperfusion induced myocyte necrosis. 5. Thus, -SH containing ACE inhibitors--which both inhibit ACE and scavenge cytotoxic free radicals--may offer a suitable form of treatment for myocardial ischaemia/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690907      PMCID: PMC1379861          DOI: 10.1111/j.1365-2125.1989.tb03592.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  42 in total

1.  Acute effects of hydralazine and enalapril on contractile function of postischemic "stunned" myocardium.

Authors:  K Przyklenk; R A Kloner
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

Review 2.  Free radicals and myocardial injury: pharmacologic implications.

Authors:  S W Werns; M J Shea; B R Lucchesi
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

3.  Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model.

Authors:  P A de Graeff; W H van Gilst; K Bel; C D de Langen; J H Kingma; H Wesseling
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

Authors:  W H van Gilst; P A de Graeff; H Wesseling; C D de Langen
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

5.  Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat.

Authors:  L Rochette; C Ribuot; P Belichard; A Bril; M Devissaguet
Journal:  Clin Exp Hypertens A       Date:  1987

6.  Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs.

Authors:  A Uraizee; K A Reimer; C E Murry; R B Jennings
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

7.  Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations.

Authors:  W Wijns; P W Serruys; C J Slager; J Grimm; H P Krayenbuehl; P G Hugenholtz; O M Hess
Journal:  J Am Coll Cardiol       Date:  1986-03       Impact factor: 24.094

8.  Salvage of ischaemic myocardium by reperfusion: importance of collateral blood flow and myocardial oxygen demand during occlusion.

Authors:  K Przyklenk; M T Vivaldi; F J Schoen; J Malcolm; O Arnold; R A Kloner
Journal:  Cardiovasc Res       Date:  1986-06       Impact factor: 10.787

9.  Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury.

Authors:  G Ambrosio; L C Becker; G M Hutchins; H F Weisman; M L Weisfeldt
Journal:  Circulation       Date:  1986-12       Impact factor: 29.690

10.  Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after 3 hours of occlusion followed by reperfusion.

Authors:  K P Gallagher; A J Buda; D Pace; R A Gerren; M Shlafer
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

View more
  10 in total

1.  Role of cardiac renin-angiotensin system in sarcoplasmic reticulum function and gene expression in the ischemic-reperfused heart.

Authors:  S Takeo; Y Nasa; K Tanonaka; F Yamaguchi; K Yabe; H Hayashi; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

2.  Cardiorespiratory effects of continuous i.v. administration of the ACE inhibitor enalaprilat in the critically ill.

Authors:  J Boldt; M Müller; M Heesen; K Härter; G Hempelmann
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

3.  Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction.

Authors:  Florian Leuschner; Peter Panizzi; Isabel Chico-Calero; Won Woo Lee; Takuya Ueno; Virna Cortez-Retamozo; Peter Waterman; Rostic Gorbatov; Brett Marinelli; Yoshiko Iwamoto; Aleksey Chudnovskiy; Jose-Luiz Figueiredo; David E Sosnovik; Mikael J Pittet; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circ Res       Date:  2010-10-07       Impact factor: 17.367

Review 4.  Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease.

Authors:  R Ferrari; C Ceconi; S Curello; P Pepi; A Mazzoletti; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 5.  Current concepts: converting enzyme inhibitors in coronary artery disease.

Authors:  P Thürmann; N Rietbrock
Journal:  Clin Investig       Date:  1992-01

6.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.

Authors:  X Liu; R M Engelman; J A Rousou; G A Cordis; D K Das
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

8.  Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury.

Authors:  H Suzuki; A Matsumori; Y Matoba; B S Kyu; A Tanaka; J Fujita; S Sasayama
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  The effect of angiotensin-converting enzyme inhibitors on human neutrophil chemotaxis in vitro.

Authors:  M Clapperton; J McMurray; A C Fisher; H J Dargie
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

Review 10.  An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles.

Authors:  Marcus Baumann; Ian R Baxendale
Journal:  Beilstein J Org Chem       Date:  2013-10-30       Impact factor: 2.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.